Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats.

Valenta A, Roschger P, Fratzl-Zelman N, Kostenuik PJ, Dunstan CR, Fratzl P, Klaushofer K

Bone1 Jul 2005Cited by 33 (Europe PMC)

PMID15869920DOI10.1016/j.bone.2005.03.013PepBankPUB-15869920

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In aged ovariectomized rats, PTH-treated groups increased bone volume by up to 139%, independently of OPG.
In plain wordsIn aged ovariectomized rats, PTH increased bone volume compared with vehicle, independently of OPG.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMineralized bone volume
Study
ratn: not reported in source
Aged ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 microg/kg three days per week · subcutaneous · 5.5 monthsAs given in this study (rat).
Measurements
BV/TV increase
≤ 139%
PTH-treated groups independently of OPG
Source sentences
Summary
A remarkable increase of BV/TV up to 139% (P<0.001) was observed in the PTH-treated groups independently of OPG.
3 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we examined the bone material of aged ovariectomized (OVX) rats treated either with PTH (1-34) or OPG alone or in combination of both.
Summary · context
Rats (n=68) were either sham-operated or ovariectomized (OVX) at the age of 3 months, and 15 months later, OVX animals were treated either with vehicle, OPG (10 mg/kg), PTH (80 microg/kg) or a combination of both during 5.5 months.
Summary · context
All treatments were by subcutaneous injection, 3 days per week.
Report a problemFND-1586992001

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

02AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In aged ovariectomized rats, PTH plus OPG reduced mineralization density distribution width by 8.9%.
In plain wordsIn aged ovariectomized rats, PTH plus OPG reduced the spread of bone mineralization density compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseWidth of mineralization density distribution
Study
ratn: not reported in source
Aged ovariectomized rats
Comparator
Vehicle-treated ovariectomized rats
Outcome group
Bone and joint · Musculoskeletal
Measurements
Cawidth reduction
−8.9%
PTH+OPG
Source sentences
Summary
Cawidth was reduced (-6.4%, P<0.01, and -8.9%, P<0.001) in animals treated with OPG and PTH+OPG, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we examined the bone material of aged ovariectomized (OVX) rats treated either with PTH (1-34) or OPG alone or in combination of both.
Summary · context
Rats (n=68) were either sham-operated or ovariectomized (OVX) at the age of 3 months, and 15 months later, OVX animals were treated either with vehicle, OPG (10 mg/kg), PTH (80 microg/kg) or a combination of both during 5.5 months.
Summary · context
All treatments were by subcutaneous injection, 3 days per week.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1586992002
03AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In aged ovariectomized rats, mineral particle thickness did not change across treated and untreated groups, including PTH.
In plain wordsIn aged ovariectomized rats, mineral particle thickness did not differ across treated and untreated groups, including PTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMineral particle thickness
Study
ratn: not reported in source
Aged ovariectomized rats
Comparator
Treated and untreated ovariectomized groups
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The T parameter was not altered in the trabecular bone within the group of treated and untreated OVX rats.
3 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we examined the bone material of aged ovariectomized (OVX) rats treated either with PTH (1-34) or OPG alone or in combination of both.
Summary · context
Rats (n=68) were either sham-operated or ovariectomized (OVX) at the age of 3 months, and 15 months later, OVX animals were treated either with vehicle, OPG (10 mg/kg), PTH (80 microg/kg) or a combination of both during 5.5 months.
Summary · context
All treatments were by subcutaneous injection, 3 days per week.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1586992003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.